An author correction has been issued for the SCREESCO randomized controlled trial, a major study that compared colonoscopy and fecal immunochemical testing against usual care in diagnostic colorectal cancer screening. The correction was published online in Nature Medicine, the journal that originally carried the trial's findings.
The SCREESCO trial, conducted in Sweden, was designed to evaluate whether organized screening programs using colonoscopy or FIT could reduce colorectal cancer incidence and mortality compared with the screening that typically occurs in routine clinical practice. Colorectal cancer remains one of the most commonly diagnosed malignancies worldwide, and screening strategies vary widely across health systems. The trial's randomized design gave it particular weight in ongoing debates over which screening approach offers the best balance of effectiveness, cost, and patient participation.
Author corrections are a standard part of the scientific publication process. They are issued when errors are identified in a published paper — whether in data reporting, author affiliations, funding information, or other details — and are intended to preserve the integrity of the scientific record. The correction notice does not necessarily indicate that the trial's central conclusions are invalid, but it does mean that the published record has been formally amended.
The original SCREESCO study compared three groups: participants invited to undergo colonoscopy screening, participants invited to complete FIT screening, and a control group receiving usual care. The trial's results have been closely watched by gastroenterologists, oncologists, and public health officials because they speak directly to the question of how best to structure national screening programs. Colonoscopy is highly sensitive but invasive and resource-intensive, while FIT is non-invasive, cheaper, and easier to deploy at scale, though it requires follow-up colonoscopy for positive results.
Colorectal cancer screening policy in the United States and Europe has increasingly moved toward organized programs, and evidence from randomized trials such as SCREESCO informs decisions about which tests to recommend and how to allocate limited endoscopic capacity. The correction notice, published in Nature Medicine, updates the public record for researchers, clinicians, and policymakers who rely on the trial's data.
Nature Medicine is a leading peer-reviewed journal covering translational and clinical research. Corrections are published alongside the original article and are indexed so that readers can trace changes to the scientific literature. The journal's decision to issue the correction reflects the standard editorial practice of maintaining accuracy in published research.
For patients and the public, the practical implications of an author correction are usually limited. Screening recommendations are based on the cumulative body of evidence, not a single paper, and are periodically reviewed by bodies such as the U.S. Preventive Services Task Force and European guidelines committees. Still, transparency about errors is essential to public trust in medical research, particularly for a disease where screening decisions affect millions of people each year.
The correction notice appears in the same journal that published the original trial, and the scientific community will continue to assess the SCREESCO findings as part of the broader effort to reduce deaths from colorectal cancer through effective, accessible screening.
